Immune-correlates Analysis of an HIV-1 Vaccine Efficacy Trial

Background: In the RV144 trial, the estimated efficacy of a vaccine regimen against human immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case-control analysis to identify antibody and cellular immune correlates of infection risk.

Methods: In pilot studies conducted with RV144 blood samples, 17 antibody or cellular assays met prespecified criteria, of which 6 were chosen for primary analysis to determine the roles of T-cell, IgG antibody, and IgA antibody responses in the modulation of infection risk. Assays were performed on samples from 41 vaccinees who became infected and 205 uninfected vaccinees, obtained 2 weeks after final immunization, to evaluate whether immune-response variables predicted HIV-1 infection through 42 months of follow-up.

Results: Of six primary variables, two correlated significantly with infection risk: the binding of IgG antibodies to variable regions 1 and 2 (V1V2) of HIV-1 envelope proteins (Env) correlated inversely with the rate of HIV-1 infection (estimated odds ratio, 0.57 per 1-SD increase; P=0.02; q=0.08), and the binding of plasma IgA antibodies to Env correlated directly with the rate of infection (estimated odds ratio, 1.54 per 1-SD increase; P=0.03; q=0.08). Neither low levels of V1V2 antibodies nor high levels of Env-specific IgA antibodies were associated with higher rates of infection than were found in the placebo group. Secondary analyses suggested that Env-specific IgA antibodies may mitigate the effects of potentially protective antibodies.

Conclusions: This immune-correlates study generated the hypotheses that V1V2 antibodies may have contributed to protection against HIV-1 infection, whereas high levels of Env-specific IgA antibodies may have mitigated the effects of protective antibodies. Vaccines that are designed to induce higher levels of V1V2 antibodies and lower levels of Env-specific IgA antibodies than are induced by the RV144 vaccine may have improved efficacy against HIV-1 infection.

Citing Articles

A Pentavalent HIV-1 Subtype C Vaccine Containing Computationally Selected gp120 Strains Improves the Breadth of V1V2 Region Responses.

Shen X, Korber B, Spreng R, Sawant S, deCamp A, McMillan A Vaccines (Basel). 2025; 13(2).

PMID: 40006680 PMC: 11860947. DOI: 10.3390/vaccines13020133.

NK cell depletion in bispecific antibody therapy is associated with lack of HIV control after ART interruption.

Sanchez-Gaona N, Perea D, Curran A, Burgos J, Navarro J, Suanzes P Commun Biol. 2025; 8(1):236.

PMID: 39953264 PMC: 11829058. DOI: 10.1038/s42003-025-07651-6.

Increased Chemokine Production is a Hallmark of Rhesus Macaque Natural Killer Cells Mediating Robust Anti-HIV Envelope-Specific Antibody-Dependent Cell-Mediated Cytotoxicity.

Nohara J, Evangelous T, Berry M, Beck W, Mudrak S, Jha S Pathog Immun. 2025; 10(1):49-79.

PMID: 39911143 PMC: 11792536. DOI: 10.20411/pai.v10i1.734.

A Phase 1 randomized trial of homologous and heterologous filovirus vaccines with a late booster dose.

Rostad C, Yildirim I, Kao C, Yi J, Kamidani S, Peters E NPJ Vaccines. 2024; 9(1):255.

PMID: 39715748 PMC: 11666633. DOI: 10.1038/s41541-024-01042-4.

Safety and immunogenicity of CD40.HIVRI.Env, a dendritic cell-based HIV vaccine, in healthy HIV-uninfected adults: a first-in-human randomized, placebo-controlled, dose-escalation study (ANRS VRI06).

Levy Y, Moog C, Wiedemann A, Launay O, Candotti F, Hardel L EClinicalMedicine. 2024; 77:102845.

PMID: 39649135 PMC: 11625018. DOI: 10.1016/j.eclinm.2024.102845.

References

Gorny M, Stamatatos L, Volsky B, Revesz K, Williams C, Wang X . Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J Virol. 2005; 79(8):5232-7. PMC: 1069558. DOI: 10.1128/JVI.79.8.5232-5237.2005. View

Griffiss J, Goroff D . IgA blocks IgM and IgG-initiated immune lysis by separate molecular mechanisms. J Immunol. 1983; 130(6):2882-5. View

Mascola J . Defining the protective antibody response for HIV-1. Curr Mol Med. 2003; 3(3):209-16. DOI: 10.2174/1566524033479799. View

Changela A, Wu X, Yang Y, Zhang B, Zhu J, Nardone G . Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1. J Virol. 2010; 85(6):2524-35. PMC: 3067962. DOI: 10.1128/JVI.02335-10. View

Hansen S, Ford J, Lewis M, Ventura A, Hughes C, Coyne-Johnson L . Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature. 2011; 473(7348):523-7. PMC: 3102768. DOI: 10.1038/nature10003. View

Forthal D, B Gilbert P, Landucci G, Phan T . Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol. 2007; 178(10):6596-603. DOI: 10.4049/jimmunol.178.10.6596. View

Picker L, Hansen S, Lifson J . New paradigms for HIV/AIDS vaccine development. Annu Rev Med. 2011; 63:95-111. PMC: 3368276. DOI: 10.1146/annurev-med-042010-085643. View

McLellan J, Pancera M, Carrico C, Gorman J, Julien J, Khayat R . Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature. 2011; 480(7377):336-43. PMC: 3406929. DOI: 10.1038/nature10696. View

Buchbinder S, Mehrotra D, Duerr A, Fitzgerald D, Mogg R, Li D . Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008; 372(9653):1881-1893. PMC: 2721012. DOI: 10.1016/S0140-6736(08)61591-3. View

10.

Barnett S, Burke B, Sun Y, Kan E, Legg H, Lian Y . Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant. J Virol. 2010; 84(12):5975-85. PMC: 2876657. DOI: 10.1128/JVI.02533-09. View

11.

Onyango-Makumbi C, Omer S, Mubiru M, Moulton L, Nakabiito C, Musoke P . Safety and efficacy of HIV hyperimmune globulin for prevention of mother-to-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda (HIVIGLOB/NVP STUDY). J Acquir Immune Defic Syndr. 2011; 58(4):399-407. PMC: 3204156. DOI: 10.1097/QAI.0b013e31822f8914. View

12.

Jarvis G, Griffiss J . Human IgA1 blockade of IgG-initiated lysis of Neisseria meningitidis is a function of antigen-binding fragment binding to the polysaccharide capsule. J Immunol. 1991; 147(6):1962-7. View

13.

Borgan O, Langholz B, Samuelsen S, Goldstein L, Pogoda J . Exposure stratified case-cohort designs. Lifetime Data Anal. 2000; 6(1):39-58. DOI: 10.1023/a:1009661900674. View

14.

Rolland M, Gilbert P . Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide. AIDS Res Hum Retroviruses. 2011; 28(4):400-4. PMC: 3316118. DOI: 10.1089/aid.2011.0240. View

15.

Barouch D, Liu J, Li H, Maxfield L, Abbink P, Lynch D . Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature. 2012; 482(7383):89-93. PMC: 3271177. DOI: 10.1038/nature10766. View

16.

Walker L, Phogat S, Chan-Hui P, Wagner D, Phung P, Goss J . Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 2009; 326(5950):285-9. PMC: 3335270. DOI: 10.1126/science.1178746. View

17.

Nitayaphan S, Pitisuttithum P, Karnasuta C, Eamsila C, de Souza M, Morgan P . Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J Infect Dis. 2004; 190(4):702-6. DOI: 10.1086/422258. View

18.

Hessell A, Rakasz E, Tehrani D, Huber M, Weisgrau K, Landucci G . Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol. 2009; 84(3):1302-13. PMC: 2812338. DOI: 10.1128/JVI.01272-09. View

19.

Plotkin S . Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis. 2008; 47(3):401-9. DOI: 10.1086/589862. View

20.

Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R . Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009; 361(23):2209-20. DOI: 10.1056/NEJMoa0908492. View